Table 1 Eligibility Criteria

• R0/R1 resected pancreatic ductal adenocarcinoma

• Metastatic disease

• Adequate lab parameters (bone marrow-, liver and kidney function; Hb >8.0 g/dl, WBC >3,000 cells/mm³, platelets >75,000 cells/mm³; ALT/AST ≤ 2 ULN; Creatinine ≤1.5 mg/dL and calculated or measured creatinine clearance (CrCl) of ≥ 60 ml/min).

• Previous chemo- or radiotherapy for pancreatic carcinoma

• Therapy starts within eight weeks after surgery

• Previous radiotherapy in the corresponding region

• Ability of patient to understand character and individual consequences of clinical trial

• Patients with known severe depression

• Written informed consent must be available before enrolment in the trial

• Patients with severe heart diseases (NYHA stadium three and four) or severe lung disease (COPD Grade III, Asthma bronchiale Grade IV)

• For women with childbearing potential, adequate contraception.

• General condition worse than ECOG 2

• Age ≥ 18 years

• Pregnancy and lactation

• History of hypersensitivity to the investigational product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational product

• Any contraindication met for any investigational product

• Patients with mental diseases ICD-10-code F30, F31, F32.2 ff. or F33.2 ff.

• Participation in other clinical trials and observation period of competing trials, respectively.

• Serious uncontrolled acute infections at the time of therapy initiation or patients with known HIV infection, other immunodeficiencies or autoimmune diseases